Severe muscle disorders associated with statins: Analysis of cases notified in France up to the end of February 2002 and data concerning the risk profile of cerivastatin;Atteintes musculaires sévères sous statines: Bilan des cas notifiés en France jusqu'à fin février 2002 et données concernant les risques liés à la cérivastatine

Therapie

Volumn 60, Issue 3, 2005, Pages 299-304

  Andréjak, Michel ^a,c   Gras, Valérie ^a   Caron, Jacques ^b  

^a Service de Pharmacologie Clinique   (France)

^b Centre de Pharmacovigilance   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

Cerivastatin; Gemfibrozil; Pharmacovigilance; Severe muscular disorders; Statins

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; DILTIAZEM; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; PRAVASTATIN; SIMVASTATIN; VERAPAMIL; ANTILIPEMIC AGENT; PYRIDINE DERIVATIVE;

ADULT; AGED; CONTROLLED STUDY; DISEASE SEVERITY; DRUG INDUSTRY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FRANCE; HUMAN; MAJOR CLINICAL STUDY; MUSCLE DISEASE; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK FACTOR; ARTICLE; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; FEMALE; MALE; OUTPATIENT; RISK ASSESSMENT;

AGED; ANTILIPEMIC AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; FRANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MUSCULAR DISEASES; OUTPATIENTS; PRODUCT SURVEILLANCE, POSTMARKETING; PYRIDINES; RISK ASSESSMENT;

EID: 24944577518     PISSN: 00405957     EISSN: 00405957     Source Type: Journal    
DOI: 10.2515/therapie:2005040     Document Type: Article

References (19)

1. Stamler M, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded? Finding in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA 1986; 256: 2823-8
2. Luc G. Hypolipémiants : bilan des grandes études cardiovasculaires. Therapie 2003; 58: 23-9
3. Andrejak M. Prise en charge du patient dyslipidémique dans la population générale adulte. In : Massy Z, Andreeli F, Andrejak M, et al., editors. Cholestérol et triglycérides : collection conduites. Paris : Editeur Doin, 2004: 23-41
4. Andrejak M, Gras V, Massy ZA, et al. Effets indésirables des statines. Therapie 2003; 58: 77-83
5. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002; 137: 581-5
6. Mittmann N, Knowles SR, Gomez M, et al. Evaluation of the extent of under-reporting of serious adverse drug reactions. Drug Saf 2004; 27 (7): 477-87
7. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289: 1681-90
8. Chang JT, Staffa JA, Park M, et al. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 2004; 13: 417-26
9. Weil A, Paita M, Saba G, et al. Cérivastatine et gemfibrozil : les données de remboursement de juin 2001 du régime général de l'assurance maladie. Doc Service médical, nov 2001 [online]. Available from URL: http://www.ameli.fr [Accessed 2005 May 16]
10. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-90
11. Backman JT, Kyrklund C, Neuvonen M, et al. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 2002; 72: 685-91
12. Wang JS, Neuvonen M, Wen X, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002; 30: 1352-6
13. Backman JT, Kyrklund C, Kivistö KT, et al. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000; 68: 122-9
14. Kyrklund C, Backman JT, Neuvonen M, et al. Gemfibrozil increases plasma concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538-44
15. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004; 75: 455-63
16. Mück W. Rational assessment of the interaction profile of cerivastatin supports its low propensity for drug interactions. Drugs 1998; 56 Suppl. 1: 15-23
17. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003; 163: 553-64
18. Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 2004; 147: 956-65
19. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346: 539-40